| Title |
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
|
|---|---|
| Published in |
Biologics: Targets & Therapy, April 2014
|
| DOI | 10.2147/btt.s41481 |
| Pubmed ID | |
| Authors |
Dario Kivelevitch, Bobbak Mansouri, Alan Menter |
| Abstract |
Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis. |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Denmark | 1 | <1% |
| Greece | 1 | <1% |
| Unknown | 102 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 13% |
| Student > Bachelor | 14 | 13% |
| Student > Master | 13 | 12% |
| Researcher | 12 | 11% |
| Other | 12 | 11% |
| Other | 21 | 20% |
| Unknown | 21 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 42% |
| Agricultural and Biological Sciences | 10 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Nursing and Health Professions | 3 | 3% |
| Other | 9 | 8% |
| Unknown | 26 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2014.
All research outputs
#22,759,452
of 25,373,627 outputs
Outputs from Biologics: Targets & Therapy
#245
of 284 outputs
Outputs of similar age
#208,097
of 239,202 outputs
Outputs of similar age from Biologics: Targets & Therapy
#7
of 12 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,202 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.